This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
At the end of each chapter in “Rebel Health: A Field Guide to the Patient-Led Revolution in Medical Care,” there’s a box. It summarizes the chapter, distilling what a reader just encountered into easy-to-digest bullet points. The author, Susannah Fox, admits she stole that idea from “The Long Covid Survival Guide,” which was written by patients for patients.
David Reese calls it a “hinge moment” — the turning point when biotech and big tech merge to attack human disease with artificial intelligence. At Amgen, where he’s led drug research and development since 2018, Reese said this moment has finally arrived. The proof lies not only in organizational changes, such as his recent appointment as the company’s first chief technology officer, but also in Amgen’s broader push to embed AI into every aspect of the dr
Three-in-four consumers still feel concerned about rising prices, even as inflation moderates, according to Deloitte’s 2024 U.S. Retail Industry Outlook.
Despite previously suggested benchmarks, investigators found that spending less time-in-range (TIR) can still improve maternal and perinatal outcomes among pregnant patients with type 1 diabetes (T1D).
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
A critical government advisory committee charged with charting U.S. vaccination policy appears to be atrophying, jeopardizing timely decision-making on how vaccines should be used in this country. The Advisory Committee on Immunization Practices, which has in recent years been a 15-person panel, has eight vacancies — one of which dates back more than a year.
A critical government advisory committee charged with charting U.S. vaccination policy appears to be atrophying, jeopardizing timely decision-making on how vaccines should be used in this country. The Advisory Committee on Immunization Practices, which has in recent years been a 15-person panel, has eight vacancies — one of which dates back more than a year.
A new study found that over a quarter of participants with type 1 daiebets exhibited clinically relevant levels of posttraumatic stress symptoms related to a diabetes event that they experienced.
With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.
The investigators found that perceived racism in everyday life was not associated with a higher risk of coronary heart disease—only racism in the 3 specific categories.
Three years ago, Jamie Lin, an early-career nephrologist at MD Anderson Cancer Center, made findings that could potentially help both save the kidneys of cancer patients and propel her career as a physician-scientist hoping to one day run her own lab. It was a promising start, but that’s when Lin says one of the Texas institute’s most powerful researchers interfered.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
The "small molecule penalty" becomes even riskier for investors as the IRA negotiates prices, and VCs and lawmakers are looking to get a jump on those headwinds.
Last week, Biogen announced it will cease both the study and sale of Aduhelm, its FDA-approved monoclonal antibody for the treatment of Alzheimer’s disease. Its decision, the company explained, is not a response to new data about the drug’s safety or efficacy, but instead “a reprioritization of resources.” Simply put, it wasn’t about science or medicine.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday. Eli Lilly reported during its fourth quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
As acute and chronic diabetes complications increase, particularly among younger and socioeconomically disadvantaged populations, out-of-pocket costs remain a barrier to accessing essential medications.
Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers. Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations.
Light-to-moderate alcohol consumption offers more protection against ischemic heart disease (IHD) mortality for individuals with higher socioeconomic status, potentially due to unequal access to health care.
The study authors note that to effectively implement tools, processes, and strategies within practices, the stigma surrounding cognitive impairment must be addressed.
In recent months, the federal government has repeatedly told Medicare Advantage insurers that they cannot use artificial intelligence or algorithms to deny medical services the government routinely covers. But in finalizing a rule to that effect, it also stepped into a thicket of questions from insurers about a technology that is especially difficult to pin down: What is AI?
As a result of an increase in adolescent inpatient visits with a sexually transmitted infection (STI) diagnosis in 2020, further work is needed to improve STI care, particularly for this demographic.
Centene posted $45 million in profit for the fourth quarter of 2023, with its profitability for the full year growing notably compared to 2022. | Centene posted $45 million in profit for the fourth quarter of 2023, with its profitability for the full year growing notably compared to 2022.
Documents released this week shed new light on an aggressive strategy from vape maker Juul to court Black leaders, including the Rev. Al Sharpton, to publicly support its e-cigarettes. Beginning in 2018, Juul executives, including the company’s CEO, discussed six- and seven-figure partnerships with civil rights organizations, one of which would have seen it send as much as $7 million to Sharpton’s group, according to internal emails and documents that were released this week as par
Explore the commercial research landscape in the UK and the evolution of the National Institute for Health Research (NIHR) through an informative webinar.
Banking on telehealth to reach rural patients, University of Rochester Medical Center rolls out innovative virtual care pilot hlandi Fri, 02/09/2024 - 14:36
Investigators also found that the mortality rates for cardiovascular disease from 2020 to 2022 reversed the improvements of reduced mortalities in the preceding decades.
139
139
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content